ERBB2 and gallbladder cancer: The epidermal growth factor receptor (EGFR), fibroblast growth factor (FGFR), human epidermal growth factor receptor 2 (HER2), and PD-1/PD-L1 have all been used successfully as therapeutic targets in clinical trials among the numerous genomic alterations identified in GBC (Ho et al., 2022), and this has resulted in an evolving paradigm for the treatment of gallbladder cancer.